Pfizer (NYSE:PFE) Upgraded by Hsbc Global Res to “Strong-Buy” Rating

Pfizer (NYSE:PFE) was upgraded by stock analysts at Hsbc Global Res to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Down 1.0 %

PFE stock opened at $25.73 on Monday. Pfizer has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a market cap of $145.79 billion, a PE ratio of 18.24, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The business’s 50-day simple moving average is $26.28 and its 200 day simple moving average is $27.18. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the business earned $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, research analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pfizer

Institutional investors and hedge funds have recently made changes to their positions in the company. Swedbank AB boosted its stake in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares during the period. United Bank boosted its stake in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after purchasing an additional 1,277 shares during the period. Entropy Technologies LP acquired a new position in Pfizer in the 3rd quarter worth $860,000. GSA Capital Partners LLP boosted its stake in Pfizer by 87.6% in the 3rd quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock worth $949,000 after purchasing an additional 15,310 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its position in Pfizer by 52.6% during the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 31,723 shares of the biopharmaceutical company’s stock worth $919,000 after buying an additional 10,938 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.